P53 Status as Effect Modifier of the Association Between Pre-Treatment Fasting Glucose and Breast Cancer Outcomes in Non Diabetic, HER2 Positive Patients Treated With Trastuzumab

Oncotarget - United States
doi 10.18632/oncotarget.2060
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

Cardio-Oncology
2019English

Trastuzumab Use in Older Patients With HER2-positive Metastatic Breast Cancer: Outcomes and Treatment Patterns in a Whole-Of-Population Australian Cohort (2003–2015)

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy